39 /100
MEDIUM RISK
Score updated Jul 14, 2026

ATYR — aTyr Pharma, Inc. Dilution Risk Tracker

Track ATYR dilution risk with DilutionWatch's stock tracker. DilutionScore™ measures dilution risk across 5 factors — lower scores indicate higher risk of share dilution.

⚠️ Not financial advice. Do your own research before making any investment decisions.

🔔 Track ATYR — Get alerts when the score changes →

As of July 14, 2026, aTyr Pharma, Inc. (ATYR) has a DilutionWatch DilutionScore of 39/100, rated MEDIUM dilution risk. aTyr Pharma, Inc. has a market capitalization of $53.19M, 98.05M shares outstanding, 113 institutional holders tracked. Key dilution vectors include approximately 21 months of cash runway.

Source: DilutionWatch (dilutionwatch.com) — data updated daily from SEC EDGAR filings. Not financial advice.

📊 Score Breakdown

📋 Offering Ability
46
💰 Cash Runway
25
📊 Float Risk
15
⚠️ Warrant Exposure
40
🔄Convertible Debt

🌦️ Dilution Forecast

🌥️
Advisory
Moderate dilution signals present
39%
🔄 Reverse Split 55%
• 50-day avg $0.74 below $1 exchange minimum
🔁 Convertible Conversion 40%
• Significant convertible debt: 19% potential dilution
• Elevated convertible risk (60/100)
🔔 Track ATYR — Get forecast alerts →

💹 Market Data

Market Cap$53.19M
Shares Outstanding98.05M
Float95.61M
Cash$89.01M
Debt$5.80M
Short InterestN/A

🏛 Institutional Holdings

QoQ: ↑ 14.6% shares (2026Q1 vs prior)
113 institutional holders · 65.31M shares
#1 FMR LLC 14.71M shares
#2 FEDERATED HERMES, INC. 10.51M shares
#3 VANGUARD CAPITAL MANAGEMENT LLC 7.62M shares
+ 17 more holders Sign up free to view →

📉 Short Interest

Short Interest14.51M
Days to Cover5.1
% of Float15.2%
FINRA data as of Jun 30, 2026

📁 Recent SEC Activity

xbrl XBRL WARRANT Jul 07, 2026
xbrl XBRL CONVERTIBLE Dec 31, 2015
4 INSIDER TRANSACTION Feb 04, 2026
4 INSIDER TRANSACTION Feb 04, 2026
4 INSIDER TRANSACTION Feb 04, 2026
Full SEC filing analysis available with free account

📰 Recent News

No recent news

📋 What This Means for ATYR Shareholders

aTyr Pharma, Inc. (ATYR) has a DilutionScore of 39/100, rated Medium dilution risk. This tier indicates some dilution exposure — often an older shelf registration with remaining capacity, warrants not yet exercised, or a cash position that will require monitoring over the next several quarters. Score as of July 14, 2026.

DilutionWatch's EDGAR monitoring for ATYR shows no major active dilution programs at this time. The primary risk categories — shelf registration capacity, ATM programs, warrant overhang, and cash runway — are each within normal ranges for a company of this profile. This can change quickly if a new S-3 or Form S-1 is filed.

DilutionWatch tracks over 25 SEC filing types for ATYR in real-time, scanning EDGAR every 60 seconds. The DilutionWatch screener shows real-time score changes for ATYR alongside comparable medium-risk stocks. Not financial advice — this analysis is for informational purposes only.

Track ATYR Dilution Risk in Real-Time
Get instant alerts when SEC filings impact dilution risk. Free tier available.
Start Tracking ATYR — Free
Real-time SEC alerts DilutionScore™ tracking No credit card required

🔗 Related Stocks — MEDIUM Risk

Other MEDIUM dilution risk stocks tracked by DilutionWatch with similar profiles:

Browse all 7,800+ tracked stocks →

📖 Dilution Education
→ Complete Dilution Guide for Retail Investors → Anti-Dilution Provisions Explained → Stock Dilution Red Flags to Watch → Understanding Shelf Registrations
🔬 More Research for ATYR
📊 ATYR FDA Catalyst Timeline & Biotech Grade — BiotechSigns 📡 ATYR Signal Convergence & Dark Pool Activity — StonkWhisper

Part of the Guerilla Finance research network. Cross-reference multiple data sources for better due diligence.